Species Comparisons Overview
Psilocybin mushroom species vary significantly in total psilocybin/psilocin content, alkaloid profiles, growth characteristics, and the character of the experience they produce. Species selection is one of the most consequential practical decisions for people growing or sourcing mushrooms.
Potency Overview by Species
Lab HPLC analysis provides the most reliable potency data. Total tryptamine content (psilocybin + psilocin + baeocystin + other active alkaloids) varies substantially between species and strains. Indicative ranges from available chromatography data:
| Species |
Typical Potency |
Duration |
Visual Profile |
Body Load |
| P. cubensis (average) |
Moderate (0.6–0.9% psilocybin) |
4–6 hours |
Moderate |
Low–Moderate |
| P. cubensis (potent strains: Penis Envy, Tidal Wave) |
High (1.0–2.0%+) |
4–6 hours |
High |
Moderate |
| P. azurescens |
Very High (1.0–1.8%) |
5–8 hours |
Very High |
Moderate–High (woodlovers paralysis risk) |
| P. semilanceata (Liberty Cap) |
High (0.9–1.4%) |
4–6 hours |
High |
Low |
| P. tampanensis (truffles) |
Low–Moderate (0.3–0.7%) |
3–5 hours |
Low–Moderate |
Low |
| P. cyanescens |
High (0.8–1.6%) |
5–7 hours |
High |
Moderate |
Note: Potency figures are approximate ranges from available HPLC data and should be treated as indicative, not precise. Individual samples vary significantly within species and strain. See Species Comparisons for full detail and sources.
Protocol Comparisons Overview
Protocol refers to the scheduling and dosing structure of psilocybin use — how often, what dose, and in what context. The most commonly discussed protocols fall into two categories: microdosing protocols and full-dose protocols.
Microdosing Protocol Comparison
| Protocol |
Schedule |
Dose Range |
Additional Components |
Evidence Base |
| Fadiman Protocol |
Day 1 dose, Days 2–3 off, repeat |
0.1–0.3 g dried |
None specified |
Observational studies; some double-blind RCTs (mixed results) |
| Stamets Stack |
4 days on, 3 days off |
0.1–0.3 g dried |
Lion's Mane (500mg+), Niacin (100mg+) |
Anecdotal/mechanistic rationale; limited formal evidence |
| Every Other Day |
Day 1 dose, Day 2 off, repeat |
0.1–0.2 g dried |
None specified |
Observational; higher tolerance accumulation risk than Fadiman |
| Intuitive / Spontaneous |
As needed, guided by internal cues |
Variable |
Variable |
Anecdotal; difficult to study systematically; higher escalation risk |
Preparation Method Comparisons Overview
How you consume psilocybin mushrooms affects onset time, peak intensity, duration, and GI tolerance. This comparison covers the most common approaches for dried psilocybin mushrooms.
| Method |
Onset |
Peak Intensity |
Duration |
GI Comfort |
Notes |
| Oral (dried mushrooms) |
45–90 min |
Baseline |
4–6 hours |
Moderate; chitin can cause nausea |
Most common; dosing precision moderate |
| Lemon Tek |
20–45 min |
Higher |
3–5 hours |
Variable; some find it easier |
Faster, more intense; treat same gram weight as stronger dose |
| Mushroom Tea |
30–60 min |
Similar or slightly lower |
4–5 hours |
Better; removes most chitin |
Simmer below boiling to preserve psilocybin; filter out solids |
| Capsules (ground dried) |
60–90 min |
Similar to oral |
4–6 hours |
Similar to oral |
Best for precise microdosing; slower onset than other methods |
Dosage Level Comparisons Overview
Psilocybin effects exist on a continuum from sub-perceptual microdoses through profoundly disorienting high doses. The levels below describe approximate experiences for an average-sensitivity person taking average-potency dried P. cubensis. Individual response varies significantly — metabolism, body weight, tolerance, food intake, prior experience, and mushroom potency all affect outcome at the same gram weight.
| Level |
Dose Range (dried P. cubensis) |
Primary Effects |
Risk Level |
| Microdose |
0.05–0.3 g |
Sub-perceptual; subtle mood, focus, creativity shifts reported; no hallucinations |
Low (if no contraindications) |
| Threshold |
0.3–0.75 g |
Mild perceptual changes, emotional softening, light visual enhancement; functioning generally preserved |
Low–Moderate |
| Low / Beginner |
0.75–1.5 g |
Clear perceptual effects, emotional amplification, mild visual phenomena, some introspection; manageable for most in safe setting |
Moderate |
| Moderate |
1.5–3.0 g |
Strong visual effects, significant emotional processing, time distortion, ego softening; sitter recommended for inexperienced users |
Moderate–High |
| High / Therapeutic |
3.0–5.0 g (or ~25mg synthetic) |
Potential ego dissolution, mystical experiences, deep psychological processing; used in clinical trials; sitter or guide required |
High — requires preparation and support |
| Heroic |
5.0 g+ |
Complete ego dissolution, intense visionary content, loss of ordinary identity; not used in clinical research |
Very High — not recommended without extensive prior experience and expert guidance |
Substance Comparisons Overview
This section is provided for educational context only. Psilobase does not promote or encourage the use of any substance, legal or illegal. Understanding how psilocybin compares to other compounds helps individuals assess clinical research, understand pharmacology, and evaluate therapeutic options discussed in the literature.
Psilocybin vs. LSD
Both are classical psychedelics acting primarily at 5-HT2A receptors. Key differences:
- Duration: Psilocybin 4–6 hours vs. LSD 8–12 hours. Duration management is a significant practical and safety consideration — the longer LSD experience allows more opportunity for set and setting to shift negatively.
- Character: Psilocybin experiences are commonly described as warmer, more organic, more emotionally introspective. LSD experiences are often described as more cerebral, stimulating, and analytically activating. These are population-level tendencies with significant individual variation.
- Body load: LSD produces more sympathomimetic physical effects (tachycardia, elevated body temperature, pupil dilation more pronounced). Psilocybin body load is generally lower.
- Legal status: Both are Schedule I in the US. Neither is available legally for recreational use in most jurisdictions.
- Research status: Psilocybin has substantially more current clinical trial activity and regulatory engagement. LSD research is ongoing but less advanced in the regulatory pathway.
Psilocybin vs. DMT / Ayahuasca
DMT is also a tryptamine psychedelic but with a very different pharmacological profile in its smoked form:
- Duration (smoked/vaporized): 10–30 minutes — extremely short, often described as the most intense brief psychedelic experience. No titration possible once inhaled.
- Intensity: Generally more intense and visionary at comparable doses than psilocybin. Ego dissolution is common even at moderate doses.
- Ayahuasca (oral DMT + MAOI): When combined with a monoamine oxidase inhibitor (as in ayahuasca), DMT becomes orally active and lasts 4–6 hours. MAOI interactions with other substances create significant safety complexity. The ceremonial context, preparation requirements, and purging effects of ayahuasca are distinct from psilocybin mushroom use.
- Research status: Clinical research on ayahuasca and DMT is significantly less advanced than psilocybin. Some promising early trials exist but the field is less mature.
Psilocybin vs. Ketamine
Ketamine is a dissociative anesthetic that produces psychedelic-like effects at sub-anesthetic doses. It is legally available as an FDA-approved medication (esketamine/Spravato for depression; IV/IM ketamine off-label) — the only legally accessible psychedelic-adjacent compound in most US states.
- Mechanism: Ketamine acts primarily as an NMDA receptor antagonist — different from psilocybin's 5-HT2A agonism. Different mechanism, different experience character.
- Duration: 1–2 hours (IV/IM), making sessions shorter and more medically controllable
- Dependence risk: Ketamine has meaningful dependence potential that psilocybin lacks — frequent use can produce psychological and potentially physiological dependence
- Legal access: Available through licensed ketamine clinics — no clinical trial enrollment required. This makes it the only currently accessible legal option for most US patients.
Psilocybin vs. MDMA
MDMA is an empathogen/entactogen — not a classical psychedelic — primarily releasing serotonin, dopamine, and norepinephrine rather than acting as a receptor agonist.
- Mechanism: Monoamine release vs. 5-HT2A agonism — fundamentally different pharmacology producing different experiences
- Effects character: MDMA primarily produces profound feelings of emotional closeness, empathy, and reduced fear — without the perceptual alterations or ego dissolution typical of classical psychedelics at moderate doses
- Therapeutic application: MDMA-assisted therapy (MAPS Phase 3) is specifically for PTSD, leveraging MDMA's fear-extinction properties during trauma processing. Not interchangeable with psilocybin therapy.
- Neurotoxicity: High-dose or frequent MDMA use produces serotonergic neurotoxicity in animal models. Clinical MDMA-AT doses are much lower than recreational doses; neurotoxicity is not demonstrated at clinical doses in human studies.
Therapy Model Comparisons Overview
Psilocybin-assisted therapy is not a single standardized treatment — multiple therapeutic models have been developed and are used in different clinical research contexts. Understanding how they differ helps in evaluating research and in choosing trained practitioners.
Psilocybin-Assisted Therapy vs. Traditional CBT
Cognitive Behavioral Therapy (CBT) is the most evidence-supported psychotherapy for depression and anxiety. The most directly comparative published data comes from the Imperial College London trial (NEJM 2021), which compared psilocybin therapy to escitalopram (SSRI) — not CBT specifically. Both showed antidepressant effects; psilocybin showed faster onset and higher rates of patients in remission on some measures.
Direct psilocybin vs. CBT comparisons are limited. Mechanistically, they may work differently and complementarily: CBT modifies explicit thought patterns through repetitive behavioral practice; psilocybin (per the REBUS model) may allow rapid updating of deep predictive beliefs through a single or small number of sessions. Some researchers hypothesize that psilocybin may potentiate CBT by increasing neuroplasticity in the window following sessions — an active research question.
Psilocybin-Assisted Therapy vs. EMDR
Eye Movement Desensitization and Reprocessing (EMDR) is widely used for trauma and PTSD. Like psilocybin therapy, EMDR is thought to work through enabling the reprocessing of traumatic memories in a way that reduces their emotional charge. No published head-to-head trials exist. In clinical practice, some therapists use both — EMDR in standard sessions and psilocybin therapy for sessions requiring deeper psychological processing. The two approaches may be complementary rather than competitive for trauma presentations.
Psilocybin Therapy Models Compared
- EMBARK Model (NYU/Columbia): Existential, Meaning-centered, Body-based, Altered-states, Relational, Kriya/spiritual. Integrative across traditions; strong attention to existential and spiritual dimensions. Best documented in cancer-related distress and depression contexts.
- ACE Model (Acceptance and Commitment-based): Integrates ACT framework with psilocybin experience. Emphasizes psychological flexibility and values clarification. Less widely published than EMBARK.
- Inner Healing Intelligence Model (MAPS): Developed for MDMA-AT but influences psilocybin facilitation practice. Centers the participant's own inner capacity for healing; minimizes therapist interpretation and direction during sessions. Emphasizes trusting the process.
- Supportive Mindfulness: Used in some academic trials. Facilitators provide minimal direction, encouraging mindful awareness and acceptance of whatever arises. Avoids therapeutic interpretation during sessions.
Integration Approach Comparisons
Integration is the work of making meaning from psychedelic experiences and translating insights into lasting life change. Different integration approaches have different strengths:
- Therapy-based integration: Working with a licensed therapist trained in psychedelic integration — the most structured and professionally supported approach. Recommended for complex psychological presentations, trauma history, or if the experience was significantly difficult.
- Community/group integration: Integration circles, online communities, and peer support groups. Lower cost, more accessible, but lacks professional clinical support. Most appropriate for processing positive or moderately complex experiences.
- Journaling and reflective practice: Self-directed. Highly accessible but requires self-discipline and may miss patterns that a skilled observer would notice. Best as a complement to other integration approaches rather than the sole method for complex experiences.
- Somatic integration: Body-based practices (yoga, breathwork, somatic therapy) addressing how experience is held in the body. Particularly relevant for trauma-adjacent experiences where cognitive processing alone misses the somatic dimension.
How to Read These Comparisons
Every guide uses consistent criteria so you can make confident decisions. Look for onset/peak/duration timelines, potency ranges, risk factors, required equipment, evidence source labeling, and best-fit scenarios.
Methodology
- Standardized terminology for doses, settings, and extraction strengths
- Evidence hierarchy clearly labeled: peer-reviewed RCT > clinical case series > expert consensus > community survey data
- Risk/benefit ratios expressed with caveats and contraindications clearly surfaced
- Cost, time, and complexity scored to simplify practical decision-making
When to Use Each Guide
- Species: Choosing between potency, visual character, and growing difficulty
- Protocols: Selecting microdosing or therapeutic scheduling structures
- Methods: Deciding on preparation technique based on desired onset and intensity
- Dosages: Matching intent to safe, evidence-based starting ranges
- Substances: Understanding clinical research context comparing psychedelic compounds
- Therapeutic approaches: Evaluating what therapy model or integration support to seek
Decision Aids
Each detailed comparison page includes a structured table of criteria: onset, duration, potency variability, risk factors, equipment needed, and best-fit scenarios. Use the table to shortlist, then read the narrative section for nuance that numbers alone cannot capture.
Data Transparency
Each comparison labels its evidence source: peer-reviewed RCT, clinical case series, expert consensus, or community survey data. Where evidence is thin or anecdotal, that is stated explicitly. Silence is not confirmation.
Safety First
Every comparison surfaces contraindications and harm-reduction notes for each option. Where two options are equivalent in efficacy but differ in risk, the lower-risk option is explicitly marked as the recommended starting point.
Frequently Asked Questions
How are potency ranges determined in species comparisons?
Lab chromatography data (HPLC) is used where available. For dried mushrooms, psilocybin content ranges from approximately 0.2–2%+ by dry weight depending on species, strain, growing conditions, and drying method. Field reports are cross-referenced against lab data but treated as secondary evidence. The Hyphae Cup and Oakland Hyphae potency competition has generated substantial community HPLC data. For any specific sample, the only way to know true potency is laboratory testing of that sample — gram weight without potency data is a rough approximation.
Can I mix elements from different microdosing protocols?
Yes, with care. Combining the Fadiman every-third-day schedule with Lion's Mane supplementation is straightforward — the scheduling structure remains the same, the supplement is simply added. Adding niacin to create a Stamets Stack-adjacent approach is reasonable but adds GI flush effects at higher niacin doses. What requires more caution is combining any microdosing protocol with ongoing SSRI use — psilocybin and SSRIs interact through the serotonergic system in ways that can both blunt psilocybin effects and (at higher doses) theoretically increase serotonin syndrome risk. Medical supervision is required for this combination.
Why are some comparison scores qualitative rather than numeric?
Not all domains have sufficient quantitative data. Subjective experience quality, spiritual significance, and relational aspects of integration resist precise measurement — qualitative descriptors with explicit confidence intervals are more honest than false precision. Additionally, individual variation is substantial enough in some domains that a single numeric score would be misleading regardless of data quality.
Do these comparisons account for individual variation?
They present population-level patterns. Individual responses vary based on genetics (CYP2D6 metabolizer status affects psilocybin processing to some degree), set, setting, prior experience, and concurrent medications. Use comparisons as starting frameworks, not final prescriptions. The threshold dose or the "typical" species potency is a starting point for a first experience — your individual response may differ significantly from population averages.
How often are these guides updated?
Major revisions follow significant new publications or regulatory changes. The clinical trial landscape is moving rapidly — check the Research section for the latest trial updates and the News section for regulatory developments. Potency comparison data is updated when new HPLC datasets become available from reputable sources.